Relating to a review of anti-obesity medications by the department of health and human services and the department of administrative services for purposes of the medical assistance program and health insurance plans for public employees

Where it is now

1. ✓
   Done: IntroducedFebruary 18, 2025
2. ✓
   Done: SubcommitteeFebruary 18, 2025
3. ✓
   Done: Senate committeeMarch 5, 2025
4. Next: Passes the Senate
5. Next: House committeeFunnel: by March 20, 2026
6. Next: Passes the House
7. Next: To the Governor
8. Next: Signed into law

Became SF 552 → Its progress continues under the new number. Go to SF 552 What’s a funnel?

What’s in it

This bill relates to the department of health and human services (HHS) and the department of administrative services (DAS) review of anti-obesity medication for purposes of the medical assistance program and health insurance plans established pursuant to Code chapter 509A for public employees. The bill requires HHS and DAS to review anti-obesity medications, including GLP-1 agonists, for effectiveness, comorbidities, cost savings, and eligibility requirements as described in the bill. HHS and DAS shall submit a report to the general assembly by January 5, 2026, containing HHS’s and DAS’s findings and proposed eligibility requirements.

From the explanation printed with the bill as introduced, written by the Legislative Services Agency. Amendments adopted later aren’t reflected. Full bill text

Senate subcommittee

Named February 18, 2025. On February 20, 2025 it recommended amendment and passage.

• Sen. Mike Klimesh REmail
• Sen. Sandy Salmon REmail
• Sen. Zach Wahls DEmail

Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part

Family tree

Where this legislation came from and where it went: earlier tries, the versions it moved through this Assembly, and later bills built on it.

Earlier and later bills are matched by wording or an identical title; check the text to be sure it’s the same idea.